Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials (Q33419419)

26 July 2017

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials (English)

1 reference

26 July 2017

phase II clinical trial

0 references

placebo

0 references

author name string

José M Garcia

1

1 reference

26 July 2017

Ralph V Boccia

2

1 reference

26 July 2017

Charles D Graham

3

1 reference

26 July 2017

Ying Yan

4

1 reference

26 July 2017

Elizabeth Manning Duus

5

1 reference

26 July 2017

Suzan Allen

6

1 reference

26 July 2017

John Friend

7

1 reference

26 July 2017

16 December 2014

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

16

1 reference

26 July 2017

108-116

1 reference

26 July 2017

1

1 reference

Definition and classification of cancer cachexia: an international consensus

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Cachexia as a major underestimated and unmet medical need: facts and numbers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Current pharmacotherapy options for cancer anorexia and cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Megestrol acetate for treatment of anorexia-cachexia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Acute effects of ghrelin administration on glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Intracerebroventricular interleukin-6 treatment decreases body fat in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Metabolic effects of interleukin-6 in human splanchnic and adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

The role of ghrelin in anorexia-cachexia syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Grip strength, body composition, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Validation of the Edmonton Symptom Assessment Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Importance of lean body mass in the oncologic patient

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

IGF-1 is downregulated in experimental cancer cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Effect of growth hormone on tumor and host in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971154-4

7 January 2021

10.1016/S1470-2045(14)71154-4

Identifiers

DOI

1 reference

26 July 2017

1 reference